Key Takeaways Gilead will acquire Ouro Medicines for $1.675B upfront plus $500M in milestones, boosting its pipeline.GILD gains OM336, a bispecific T-cell engager showing early promise in autoimmune diseases like AIHA and ITP.GILD is exploring a partnership with Galapagos to co-develop OM336 and share development costs and royalties.Gilead Sciences (GILD) has agreed to acquire privately held biotechnology company Ouro Medicines, strengthening its push into innovative therapies for autoimmune diseases.The de ...

Gilead Sciences is set to acquire Ouro Medicines for $2.2bn, marking the company’s first move into the T-cell engager (TCE) space and a deepening of ties with long-term partner, Galapagos. Through this deal, the California-based big pharma company will hand over $1.68bn upfront, while pledging up to $500m in milestone payments to absorb the latter’s BCMA/CD3-targeting TCE, gamgertamig (OM336). The therapy is currently in clinical development for antibody-mediated orphan diseases such as immune thrombocyto ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Gilead plans to develop Ouro's lead drug candidate, gamgertamig, alongside a Belgian pharma company. ...

“The market woke up to some potentially good news. But follow-through on any relief rally will likely require tangible follow-through on the geopolitical front. We’re still living in a headline-driven market,” said Chris Larkin at E*Trade from Morgan Stanley.In yesterday’s trading session, Wall Street’s main stock indexes closed sharply higher after President Trump said the U.S. would postpone attacks on Iranian energy infrastructure for five days. The Magnificent Seven stocks climbed, with Tesla (TSLA) adv ...

Gilead said the deal would bolster its growing inflammation portfolio. ...

Key TakeawaysGeopolitical risk spiked as Iran launched a new wave of missiles at Israel, prompting Kuwaiti air defenses to activate and sending S&P 500 and Nasdaq futures down 0.1% in early trade.Gilead Sciences (GILD) announced a definitive agreement to acquire Ouro Medicines for $1.675 billion in upfront cash, targeting first-in-class T cell engager programs for autoimmune diseases.Australia’s economy signaled a sharp downturn as the Flash Composite PMI plunged into contraction at 47.0, while weekly consu ...

Gilead to buy biotech firm Ouro Medicines in over $2 billion deal | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivA Gilead Sciences, Inc. office is shown in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam/File Photo Purchase Licensing Rights, opens new tabCompaniesGilead Sciences IncFollowMarch 23 (Reuters) - Gilead Sciences (GILD.O), opens new tabsaid on Monday it would buy privately held biotech firm Ouro Medicines i ...

Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases Share -- Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead's Inflammation Portfolio -- Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases Mar 23, 2026 6:15 PM Eastern Daylight Time -- Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro ...

Purchase Licensing Rights Gilead nearing up to $2 billion buyout of biotech Ouro Medicines, FT reports | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Logos of Gilead at the company's booth at the 8th China International Import Expo (CIIE) in Shanghai, China, November 6, 2025.REUTERS/Maxim Shemetov Purchase Licensing Rights, opens new tab March 23 (Reuters) - Gilead Sciences (GILD.O), opens new tabis nearing an acquisition of biot ...